Y. Ducharme

发表

Substituted phenanthrene imidazoles as potent, selective, and orally active mPGES-1 inhibitors.

N. Méthot, D. Riendeau, Daigen Xu, 2007, Bioorganic & medicinal chemistry letters.

Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses.

Sébastien Gagné, Eric Langlois, Jean-François Truchon, 2014, Bioorganic & medicinal chemistry letters.

Discovery of disubstituted phenanthrene imidazoles as potent, selective and orally active mPGES-1 inhibitors.

N. Méthot, D. Riendeau, Daigen Xu, 2009, Bioorganic & medicinal chemistry letters.

Biarylimidazoles as inhibitors of microsomal prostaglandin E2 synthase-1.

D. Riendeau, Hugo Poirier, C. Brideau, 2010, Bioorganic & medicinal chemistry letters.

Trisubstituted ureas as potent and selective mPGES-1 inhibitors.

N. Méthot, D. Riendeau, Daigen Xu, 2011, Bioorganic & medicinal chemistry letters.

The discovery of setileuton, a potent and selective 5-lipoxygenase inhibitor.

Christine Brideau, Yves Ducharme, Marc Ouellet, 2010, ACS medicinal chemistry letters.

Optimization of a tertiary alcohol series of phosphodiesterase-4 (PDE4) inhibitors: structure-activity relationship related to PDE4 inhibition and human ether-a-go-go related gene potassium channel binding affinity.

R. Young, J. Mancini, M. Turner, 2003, Journal of medicinal chemistry.

Use of hydrogen bonds to control molecular aggregation. Extensive, self-complementary arrays of donors and acceptors

Y. Ducharme, J. Wuest, 1988 .

Improving metabolic stability of phosphodiesterase-4 inhibitors containing a substituted catechol: prevention of reactive intermediate formation and covalent binding.

Chun Xing Li, J. Yergey, D. Guay, 2002, Bioorganic & medicinal chemistry letters.

In Vitro Characterization of MK-1439, a Novel HIV-1 Nonnucleoside Reverse Transcriptase Inhibitor

Jason Burch, Yves Ducharme, Louis-Charles Campeau, 2013, Antimicrobial Agents and Chemotherapy.

2,3-Diarylthiophenes as selective EP1 receptor antagonists.

D. Denis, S. Kargman, G. O'neill, 2005, Bioorganic & medicinal chemistry letters.

Discovery of MK-7246, a selective CRTH2 antagonist for the treatment of respiratory diseases.

M. Crackower, D. Denis, R. Stocco, 2011, Bioorganic & medicinal chemistry letters.

Impact of passive permeability and gut efflux transport on the oral bioavailability of novel series of piperidine-based renin inhibitors in rodents.

Yongxin Han, S. Gagné, Y. Ducharme, 2011, Bioorganic & medicinal chemistry letters.

Discovery of L-791,943: a potent, selective, non emetic and orally active phosphodiesterase-4 inhibitor.

R. Young, C. Brideau, D. Guay, 2002, Bioorganic & medicinal chemistry letters.

The C3a receptor antagonist SB 290157 has agonist activity.

A. Therien, S. Kargman, G. O'neill, 2005, Immunology letters.

Improving metabolic stability of phosphodiesterase-4 inhibitors containing a substituted catechol: prevention of reactive intermediate formation and covalent binding.

Chun Xing Li, J. Yergey, D. Guay, 2002, Bioorganic & medicinal chemistry letters.

Substituted coumarins as potent 5-lipoxygenase inhibitors.

J. Falgueyret, D. Riendeau, C. Brideau, 2006, Bioorganic & medicinal chemistry letters.

Substituted aminopyridines as potent and selective phosphodiesterase-4 inhibitors.

C. Brideau, R. Friesen, Y. Girard, 2003, Bioorganic & medicinal chemistry letters.

Substituted 4-(2,2-diphenylethyl)pyridine-N-oxides as phosphodiesterase-4 inhibitors: SAR study directed toward the improvement of pharmacokinetic parameters.

Chun Xing Li, C. Brideau, R. Friesen, 2002, Bioorganic & medicinal chemistry letters.

Integrated application of capillary HPLC/continuous-flow liquid secondary ion mass spectrometry to discovery stage metabolism studies.

J. Yergey, Y. Ducharme, L. Trimble, 1995, Analytical chemistry.

Substituted 2-pyridinemethanol derivatives as potent and selective phosphodiesterase-4 inhibitors.

R. Young, D. Éthier, J. Mancini, 2003, Bioorganic & medicinal chemistry letters.

Design and synthesis of potent, isoxazole-containing renin inhibitors.

J. Falgueyret, M. Percival, Yongxin Han, 2012, Bioorganic & medicinal chemistry letters.

Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.

J. Falgueyret, Yongxin Han, S. Gagné, 2011, Bioorganic & medicinal chemistry letters.

Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of tertiary alcohol-bearing piperidines.

J. Falgueyret, M. Percival, Yongxin Han, 2011, Bioorganic & medicinal chemistry letters.

Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of pyridone-substituted piperidines.

J. Falgueyret, M. Percival, Yongxin Han, 2011, Bioorganic & medicinal chemistry letters.

The next generation of PDE4 inhibitors.

A. Robichaud, Z. Huang, Y. Ducharme, 2001, Current opinion in chemical biology.

Naphthalenic lignan lactones as selective, nonredox 5-lipoxygenase inhibitors. Synthesis and biological activity of (methoxyalkyl)thiazole and methoxytetrahydropyran hybrids.

J. Falgueyret, D. Riendeau, C. Brideau, 1994, Journal of medicinal chemistry.

Dioxabicyclooctanyl naphthalenenitriles as nonredox 5-lipoxygenase inhibitors: structure-activity relationship study directed toward the improvement of metabolic stability.

J. Falgueyret, D. Riendeau, C. Brideau, 1996, Journal of medicinal chemistry.

Naphthalene/quinoline amides and sulfonylureas as potent and selective antagonists of the EP4 receptor.

P. Clark, Steve Rowland, D. Denis, 2011, Bioorganic & medicinal chemistry letters.

A versatile approach to the synthesis of dinucleotide analogs containing neutral 5′-thioformacetal internucleoside linkages

Y. Ducharme, K. Harrison, 1995 .

A Versatile Approach to the Synthesis of Dinucleotide Analogues Containing Neutral 5′-Thioformacetal Internucleoside Linkages.

Y. Ducharme, K. Harrison, 2010 .

Pharmacological characterization of a selective COX-2 inhibitor MF-tricyclic, [3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone], in multiple preclinical species.

P. Clark, Steve Rowland, L. Audoly, 2007, European journal of pharmacology.

The discovery of 4-{1-[({2,5-dimethyl-4-[4-(trifluoromethyl)benzyl]-3-thienyl}carbonyl)amino]cyclopropyl}benzoic acid (MK-2894), a potent and selective prostaglandin E2 subtype 4 receptor antagonist.

P. Clark, Steve Rowland, D. Denis, 2010, Journal of medicinal chemistry.

MF63 [2-(6-Chloro-1H-phenanthro[9,10-d]imidazol-2-yl)-isophthalonitrile], a Selective Microsomal Prostaglandin E Synthase-1 Inhibitor, Relieves Pyresis and Pain in Preclinical Models of Inflammation

N. Méthot, D. Riendeau, P. Clark, 2008, Journal of Pharmacology and Experimental Therapeutics.

Discovery of 4-[1-[([1-[4-(trifluoromethyl)benzyl]-1H-indol-7-yl]carbonyl)amino]cyclopropyl]benzoic acid (MF-766), a highly potent and selective EP4 antagonist for treating inflammatory pain.

Steve Rowland, D. Denis, R. Stocco, 2010, Bioorganic & medicinal chemistry letters.

Isophthalonitrile], a Selective Microsomal Prostaglandin E Synthase-1 Inhibitor, Relieves Pyresis and Pain in Preclinical Models of Inflammation

D. Riendeau, P. Clark, Steve Rowland, 2022 .